The World’s Second Approved Biosimilars of Denosumab (MAILISHU)
biopharmaceutical company with the layout of whole industry chain, announced that the Denosumab solution for injection (trade name: MAILISHU, project code: 9MW0311), which is developed by its wholly-owned subsidiary T-mab, has been formally approved for marketing by the National Medical Products Administration (NMPA) (Approval No.: S20233111).
MAILISHU is the world’s second approved Biosimilars of Denosumab for the osteoporosis in postmenopausal women at high risk of fracture. The drug can significantly reduce the risk of vertebral, non-vertebral and hip fractures within this patient segment.
Leave a Reply